Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Falk Gastro Review Journal

    Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

    Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

    The latest issues

    Edition 4/2024

    read more

    Edition 3/2024

    read more

    Edition 2/2024

    read more

    Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

    All articles

    Colon to Rectum

    Inflammatory bowel disease is associated with an increased risk of incident acute arterial events: Analysis of the United Kingdom Biobank

    Clin Gastroenterol Hepatol. 2023;21(3):761–70.e13

    Alayo QA, Loftus EV, Jr., Yarur A, Alvarado D, Ciorba MA, de las Fuentes L, Deepak P

    Go to article

    Colon to Rectum

    Post-COVID-19 irritable bowel syndrome

    Gut. 2023;72(3):484–92

    Marasco G, Cremon C, Barbaro MR, Cacciari G, Falangone F, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ, Koc ES, Sirin G, Calıskan AR, Bengi G, Alıs EE, Lukic S, Trajkovska M, Hod K, Dumitrascu D, Pietrangelo A, Corradini E, Simren M, Sjölund J, Tornkvist N, Ghoshal UC, Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, Danese S, Portincasa P, Di Sabatino A, Maggio M, Philippou E, Lee YY, Salvi D, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; GI-COVID19 study group

    Go to article

    Colon to Rectum

    Randomized clinical trial: Efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome

    Aliment Pharmacol Ther. 2023;57(1):81–93

    Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE

    Go to article

    Colon to Rectum

    Meditation and yoga for irritable bowel syndrome: A randomized clinical trial

    Am J Gastroenterol. 2023;118(2):329–37

    D’Silva A, Marshall DA, Vallance JK, Nasser Y, Rajagopalan V, Szostakiwskyj JH, Raman M

    Go to article

    Colon to Rectum

    Long-term gastrointestinal sequelae following COVID-19: A prospective follow-up cohort study

    Clin Gastroenterol Hepatol. 2023;21(3):789–96.e1

    Golla R, Vuyyuru S, Kante B, Kumar P, Thomas DM, Makharia G, Kedia S, Ahuja V

    Go to article

    Colon to Rectum

    Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN

    Gut. 2023;72(2):338–44

    Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F

    Go to article

    Colon to Rectum

    Prognostic impact of early treatment and oxaliplatin discontinuation in patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 11 adjuvant trials

    J Clin Oncol. 2023;41(4):803–15

    Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, André T, Papamichael D, Taieb J

    Go to article

    Colon to Rectum

    Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumors 1–2 cm in size: A retrospective, Europe-wide, pooled cohort study

    Lancet Oncol. 2023;24(2):187–94

    Nesti C, Bräutigam K, Benavent M, Bernal L, Boharoon H, Botling J, Bouroumeau A, Brcic I, Brunner M, Cadiot G, Camara M, Christ E, Clerici T, Clift AK, Clouston H, Cobianchi L, Ćwikła JB, Daskalakis K, Frilling A, Garcia-Carbonero R, Grozinsky-Glasberg S, Hernando J, Hervieu V, Hofland J, Holmager P, Inzani F, Jann H, Jimenez-Fonseca P, Kaçmaz E, Kaemmerer D, Kaltsas G, Klimacek B, Knigge U, Kolasińska-Ćwikła A, Kolb W, Kos-Kudła B, Kunze CA, Landolfi S, La Rosa S, López López C, Lorenz K, Matter M, Mazal P, Mestre-Alagarda C, Morales del Burgo P, Nieveen van Dijkum EJM, Oleinikov K, Orci LA, Panzuto F, Pavel M, Perrier M, Reims HM, Rindi G, Rinke A, Rinzivillo M, Sagaert X, Satiroglu I, Selberherr A, Siebenhüner AR, Tesselaar MET, Thalhammer MJ, Thiis-Evensen E, Toumpanakis C, Vandamme T, van den Berg JG, Vanoli A, van Velthuysen MLF, Verslype C, Vorburger SA, Lugli A, Ramage J, Zwahlen M, Perren A, Kaderli RM

    Go to article

    Colon to Rectum

    Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): A randomized, open-label phase 3 study

    Lancet Gastroenterol Hepatol. 2023;8(2):133–44

    André T, Falcone A, Shparyk Y, Moiseenko F, Polo-Marques E, Csöszi T, Campos-Bragagnoli A, Liposits G, Chmielowska E, Aubel P, Martín L, Fougeray R, Amellal N, Saunders MP

    Go to article